Evidence map›Paper›PMID 40120764›Full record

ArticleJournal of biotechnology2025

An efficient lysate-based approach for biosynthesis of the pyrrolobenzodiazepine natural product tilimycin.

Monica R MacDonald, Andrew M Gulick

Abstract read
In one paragraph

Article in Journal of biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Monica R MacDonaldDepartment of Structural Biology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, SUNY, 955 Main Street, Buffalo, NY 14203, United States. Electronic address: mm452@buffalo.edu.
Andrew M GulickDepartment of Structural Biology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, SUNY, 955 Main Street, Buffalo, NY 14203, United States. Electronic address: amgulick@buffalo.edu.

Funding

Structural Studies of Nonribosomal Peptide SynthesisR35GM136235 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI GULICK, ANDREW M · 2020 to 2024
$2.0M
NIGMS NIH HHS R35 GM136235
6 · The paper itself

Abstract

Many bacteria use nonribosomal peptide synthetases (NRPSs), a family of multidomain enzymes that produce peptide natural products using an assembly line strategy. One class of such compounds are pyrrolobenzodiazepines, which have DNA alkylating activity. One example is tilimycin, a compound produced by the human gut microbiota that plays a role in epithelial damage during antibiotic-associated dysbiosis. The production of analogs of these natural products may facilitate the discovery of novel bioactive molecules. However, the synthesis of these natural products typically requires significant resources and time to produce in sufficient amounts for microbial and biochemical testing. Biocatalysis offers an environmentally friendly approach, but enzyme yield and stability, particularly with large multidomain enzymes that are often used in natural product pathways, can limit biochemical reactions with purified protein. Here, we demonstrate a cell lysate-based method to synthesize the nonribosomal peptide natural product tilimycin directly from the substrates 3-hydroxyanthranilic acid and L-proline with lysates from E. coli cell lines that express the tilimycin biosynthetic proteins. We present our protocol optimization and scale-up to produce tilimycin in a fast, efficient manner.

Indexed as

BenzodiazepinesBiological ProductsPyrrolesEscherichia coliPeptide SynthasesProlineBenzodiazepinesBiological Productsnon-ribosomal peptide synthasePeptide SynthasesProlinePyrrolespyrrolo(2,1-c)(1,4)benzodiazepineBiosynthesisCell-free extractNatural productsNonribosomal peptide synthetasesPyrrolobenzodiazepine alkylating agents

Identifiers

PMID40120764
PMCPMC12001866

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.